Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 232

Sort by

Sort Order Select

Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka

Blood (2020) 136 (7): 871–884.

https://doi.org/10.1182/blood.2019003084

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Blood (2019) 134 (Supplement_1): 4247.

https://doi.org/10.1182/blood-2019-123921

Published: 2019

Journal Articles

TFDP3 and DDX53 are Highly Re-Expressed after One Cycle of Azacitidine in Myelodysplastic Syndrome Patients Achieving Complete Response: A Cancer Testis Antigen RNA-Seq Screening

Ana M Hurtado López, Tzu Hua Chen-Liang, Joaquín Panadero, Eduardo José Salido, MD, Victor Beltrán, Begoña Muiña, Noelia Navarro-Villamor, Inés Calabria, Ana Isabel Antón, Francisco José Ortuño, Vicente Vicente, MD PhD, Andres Jerez

Blood (2018) 132 (Supplement 1): 4340.

https://doi.org/10.1182/blood-2018-99-117851

Published: 2018

Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD

Blood (2018) 132 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2018-99-117536

Published: 2018

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

Journal Articles

Low-Dose Decitabine Could Improve the Imbalance of M1/M2 Ratio in Immune Thrombocytopenia

Xia Shao, Feng Li, Luya Cheng, Pu Chen, Zhihui Min, Lili Ji, Boting Wu, Yunfeng Cheng, MD PhD

Blood (2018) 132 (Supplement 1): 1160.

https://doi.org/10.1182/blood-2018-99-113993

Published: 2018

Journal Articles

A Small Molecular Agonist of Histone Demethylase KDM3B Selectively Represses MLL -Rearranged Acute Leukemia

Xin Xu, PhD, Wilhelm G Dirks, PhD, Hans G. Drexler, MD PhD, Zhenbo Hu, MD PhD

Blood (2018) 132 (Supplement 1): 4682.

https://doi.org/10.1182/blood-2018-99-112018

Published: 2018

Journal Articles

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Blood (2018) 132 (13): 1386–1398.

https://doi.org/10.1182/blood-2018-03-838524

Published: 2018

Includes: Supplemental data

Journal Articles

DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Michael Topper, BS, Nidal Muvarak, PhD, Lora Stojanovic, BS, T Michael Creed, BS, MS, Soren Bentzen, PhD DMSc, Curt I. Civin, MD, Maria R. Baer, MD, Tami J Kingsbury, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2017) 130 (Supplement 1): 3347.

https://doi.org/10.1182/blood.V130.Suppl_1.3347.3347

Published: 2017

Journal Articles

Vitamin C Stabilizes Foxp3 Expression in Induced Treg Cells By Targeted DNA Demethylation and Prevents Murine Model of Acute Graft Versus Host Disease

Hidenori Kasahara, MD, Shinichiro Okamoto, MD PhD, Takashi Sekiya, PhD, Akihiko Yoshimura, PhD

Blood (2017) 130 (Supplement 1): 70.

https://doi.org/10.1182/blood.V130.Suppl_1.70.70

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

DUSP22 Rearrangements Identify a Molecularly Distinct Type of Anaplastic Large Cell Lymphoma Characterized By DNA Hypomethylation and Lack of Activated STAT3

Rebecca Boddicker, PhD, Surendra Dasari, PhD, Naoki Oishi, MD PhD, Guangzhen Hu, PhD, Jagmohan Sidhu, MD, Julie Cunningham, PhD, Zhifu Sun, MD, Saurabh Baheti, MS, Julie C Porcher, Stephen M Ansell, MD PhD, Nabila Nora Bennani, MD, James R. Cerhan, MD PhD, Andrew L Feldman, MD

Blood (2017) 130 (Supplement 1): 1456.

https://doi.org/10.1182/blood.V130.Suppl_1.1456.1456

Published: 2017

Journal Articles

New Generation Sequencing of Targeted Genes in Hairy Cell Leukemia Highlighted Mutations Associated to BRAF V600E anda New Recurrent Altered Gene, KDM6A, in Hairy Cell Leukemia Variant Patients

Xavier Troussard, MD, Elsa Maitre, Philippe Bertrand, Catherine Maingonnat, Pierre-Julien Viailly, Dina Naguib, MD MASTERS, Véronique Salaun, Edouard Cornet, Brigitte SOLA, Fabrice Jardin

Blood (2017) 130 (Supplement 1): 1727.

https://doi.org/10.1182/blood.V130.Suppl_1.1727.1727

Published: 2017

Journal Articles

Global and Targeted RNA-Sequencing Assessment of Cancer Testis Antigen Re-Expression Following Azacitidine in Myelodysplastic Syndromes

Ana M Hurtado, Tzu Hua Chen-Liang, Joaquín Panadero, Eduardo José Salido, MD, Victor Beltrán, Begoña Muiña, Noelia Navarro-Villamor, Inés Calabria, Ana Isabel Antón, Andres Jerez

Blood (2017) 130 (Supplement 1): 1695.

https://doi.org/10.1182/blood.V130.Suppl_1.1695.1695

Published: 2017

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate Cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative

Blood (2016) 128 (22): 1046.

https://doi.org/10.1182/blood.V128.22.1046.1046

Published: 2016

Journal Articles

Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia

Cihangir Duy, PhD, Matt Teater, M.S., Francine E. Garrett-Bakelman, MD PhD, Tak C Lee, M.S., Cem Meydan, PhD, Jacob Lowell Glass, MD PhD, Meng Li, PhD, Helai Mohammad, PhD, Kimberly Smitheman, Alan H. Shih, MD PhD, Omar Abdel-Wahab, MD, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Monica L. Guzman, PhD, Ryan G. Kruger, PhD, Caretha L. Creasy, PhD, Ross L. Levine, MD, Martin Carroll, MD, Ari Melnick, MD

Blood (2016) 128 (22): 1048.

https://doi.org/10.1182/blood.V128.22.1048.1048

Published: 2016

NARROW

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

TFDP3 and DDX53 are Highly Re-Expressed after One Cycle of Azacitidine in Myelodysplastic Syndrome Patients Achieving Complete Response: A Cancer Testis Antigen RNA-Seq Screening

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Low-Dose Decitabine Could Improve the Imbalance of M1/M2 Ratio in Immune Thrombocytopenia

A Small Molecular Agonist of Histone Demethylase KDM3B Selectively Represses MLL -Rearranged Acute Leukemia

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML

Vitamin C Stabilizes Foxp3 Expression in Induced Treg Cells By Targeted DNA Demethylation and Prevents Murine Model of Acute Graft Versus Host Disease

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

DUSP22 Rearrangements Identify a Molecularly Distinct Type of Anaplastic Large Cell Lymphoma Characterized By DNA Hypomethylation and Lack of Activated STAT3

New Generation Sequencing of Targeted Genes in Hairy Cell Leukemia Highlighted Mutations Associated to BRAF V600E anda New Recurrent Altered Gene, KDM6A, in Hairy Cell Leukemia Variant Patients

Global and Targeted RNA-Sequencing Assessment of Cancer Testis Antigen Re-Expression Following Azacitidine in Myelodysplastic Syndromes

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only